Researchers are exploring the intersection of synthetic biology and immunology, particularly in the development of CAR-T cell therapy. This involves creating programmable cells with enhanced safety and efficacy for cancer treatment, with potential applications beyond cancer. The use of synthetic genetic switches and engineered receptors is being investigated to improve the control and targeting of these therapeutic cells.